Rheumatology Advance Access originally published online on August 9, 2006
Rheumatology 2007 46(3):442-445; doi:10.1093/rheumatology/kel244
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis
Centre for Rheumatology, Royal Free Hospital, Pond Street, London NW3 2QG, UK.
Correspondence to: Christopher P. Denton, PhD, FRCP, Centre for Rheumatology, Royal Free Hospital, Pond Street, London NW3 2QG, UK. E-mail: c.denton{at}medsch.ucl.ac.uk
 |
Abstract |
|---|
Objectives. We have assessed indications, duration and tolerability of treatment with mycophenolate mofetil (MMF) in patients with diffuse cutaneous systemic sclerosis (dcSSc), and compared clinical outcome with a control cohort treated with other immunosuppressive drugs.
Methods. The clinical records of 109 patients treated with MMF and 63 control subjects receiving other immunosuppressive drugs were reviewed. Data covering a 5-yr period from commencement of treatment or until last assessment date were collected.
Results. MMF and control groups were well-matched in terms of basic demographic and clinical parameters. Treatment with MMF was very well tolerated. Of all patients, 12% experienced adverse reactions with gastrointestinal (GI) tract disturbances and infections being most frequent. MMF was discontinued due to disease stabilization in 9%, side effects in 8% and no effect on the disease activity in 14% of the patients. There was a significantly lower frequency of clinically significant pulmonary fibrosis in the MMF-treated cohort (P = 0.037) and significantly better 5-yr survival from disease onset and from commencement of treatment (P = 0.027 and P = 0.012, respectively). There was no significant difference between the two groups in terms of modified Rodnan skin score and forced vital capacity (FVC) change.
Conclusions. MMF is very well tolerated and appears to be at least as effective as the other current therapies for dcSSc. Our results provide support for further evaluation of MMF in a prospective trial.
KEY WORDS: Scleroderma, Systemic sclerosis (SSc), Treatment, Mycophenolate mofetil (MMF)
Submitted 27 March 2006;
revised version accepted 26 May 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. T. Derk, E. Grace, M. Shenin, M. Naik, S. Schulz, and W. Xiong A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis Rheumatology, December 1, 2009; 48(12): 1595 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Martini, A. V. Ramanan, F. Falcini, H. Girschick, D. P. Goldsmith, and F. Zulian Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil Rheumatology, November 1, 2009; 48(11): 1410 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Daoussis, S.-N. C. Liossis, A. C. Tsamandas, C. Kalogeropoulou, A. Kazantzi, C. Sirinian, M. Karampetsou, G. Yiannopoulos, and A. P. Andonopoulos Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study Rheumatology, September 15, 2009; (2009) kep093v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Black, M. Matucci-Cerinic, and L. Guillevin Progress in systemic sclerosis: a 10-year perspective Rheumatology, June 1, 2009; 48(suppl_3): iii1 - iii2. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Khanna, D. E. Furst, P. J. Clements, D. P. Tashkin, and M. H. Eckman Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis Med Decis Making, November 1, 2008; 28(6): 926 - 937. [Abstract] [PDF]
|
|
|
|
|
|
A. Scheja, R. Hesselstrand, M. Wildt, and A. Akesson Relapse of skin thickening after discontinuation or decrease of azathioprine therapy in a patient with diffuse cutaneous systemic sclerosis Rheumatology, December 1, 2007; 46(12): 1862 - 1863. [Full Text] [PDF]
|
|